FDA Considers Posting Names of Unapproved Drugs

Published Online: Monday, September 1, 2003
    Concern over medication mix-ups due to ?sound-alike? drugs is causing the FDA to reconsider its longstanding opposition to public disclosure of the names of drugs still in the research and development pipeline. According to officials at the FDA?s medication error prevention branch, the agency may soon propose new procedures for placing the names of unapproved drugs on the Internet?a move that some say could reduce confusion with other products and therefore lower the potential risk of medication mix-ups for patients.

Latest Articles
Acute respiratory infections such as the common cold are often accompanied by cough and congestion caused by mucus hypersecretion.
Poor medication adherence is responsible for unnecessary illness, hospitalizations, disability, and premature death, particularly among patients with chronic diseases.
Police and a CVS pharmacy are on the lookout for a man who stole several boxes of diabetic test strips.
The FDA has approved Merck’s supplemental new drug application for single-dose fosaprepitant dimeglumine for injection.
Latest Issues